Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sanofi, Takeda form Diabetes Collaboration in Japan

Published: Wednesday, July 02, 2014
Last Updated: Wednesday, July 02, 2014
Bookmark and Share
Companies have entered into an agreement to build a collaborative system within Japan in the field of diabetes awareness and education.

In the long history of diabetes treatment, both Sanofi and Takeda have brought to market numerous therapeutic drugs to treat diabetes over the years and have built up abundant knowledge and experience. By establishing this partnership, the two companies aim to offer more treatment solutions and information to healthcare professionals addressing diversified medical needs of people with diabetes. Through the agreement the two companies will also be able to expand educational activities regarding the disease.

The 2012 National Health and Nutrition Survey by the Ministry of Health, Labour and Welfare estimated that some 9.5 million Japanese are strongly suspected of having diabetes. The Ministry also predicts that the number of Japanese with diabetes will reach 15 million by 2025. One in every four people in Japan is said to be pre-diabetic, and of those who are strongly suspected of be diabetic, approximately 30% have never received sufficient treatment, according to the survey results.

To address challenges faced by diabetes patients, their families, healthcare professionals and the government, the two companies will uphold a vision that we aim to become the most trusted partners of healthcare professionals and diabetes patients in Japan. The agreement will develop solutions focused in the following three areas:

Raise public awareness of diabetes and educate on how to prevent diabetes, including lifestyle management.

Provide educational support to patients to emphasize the importance of dietary and exercise therapies and appropriate drug treatment.

Provide healthcare professionals with comprehensive information on diabetes care.

"Diabetes is too large and complex an issue for a single company, single doctor or single government to resolve on its own. Closely aligning efforts at all levels is essential to achieve a breakthrough in preventing, diagnosing and treating diabetes. To this end, we are excited to join forces with Takeda, Japan's largest pharmaceutical company and a leader in diabetes, to create this new and unique agreement to expand existing and create new approaches to improving patient care and, ultimately, improving outcomes for Japanese living with diabetes,” stated Jez Moulding, President and Representative Director, Sanofi K.K., Senior Vice President, Japan & Pacific Region

"Many effective solutions for diabetes treatment have been brought to market in the last 20 years, but many patients are still unable to meet their blood sugar control targets and many still experience complications," said Masato Iwasaki, Ph.D., Senior Vice President, Pharmaceutical Marketing Division of Takeda. "This close agreement between two leading companies in the field of diabetes holds great significance for finding solutions for diabetes treatments based on a mutual understanding of each other's vision and therapies. With such an excellent partner, we are confident that we will be better equipped to facilitate diabetes care for patients based on their individual needs."

The agreement involves no initial payment or other compensation. The manufacturing and marketing rights holder of each company’s respective products will conduct their own product promotion and collection and dissemination of product safety information.

In addition to this agreement, both parties agree to start formulation development studies of a fixed dose combination of tofogliflozin (product name: Apleway®) and alogliptin (product name: Nesina®).


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Takeda, Sanford-Burnham Launch Heart Failure Collaboration
The partners will study the potential role of several gene regulatory proteins as targets for new treatments.
Friday, May 29, 2015
Takeda Licenses Rights to Use ImmunoGen's ADC Technology
To develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets.
Friday, March 27, 2015
Takeda Announces Formalization of Takeda Oncology
Enhance discovery, development and global commercialization of cancer medicines.
Friday, December 12, 2014
Takeda Buys Vaccines Specialist Inviragen
Obtains promising vaccine candidates against dengue and hand, foot and mouth disease, advancing Takeda's commitment to vaccines and global health.
Thursday, May 09, 2013
Takeda to Acquire URL Pharma
Acquisition expands U.S. business, leadership in gout.
Thursday, April 12, 2012
Molecular Cell Publishes Data on A Novel Form of Enzyme Inhibition of A Protein Homeostasis Target
MLN4924 is said to be the first compound shown to selectively inhibit important cancer target.
Monday, January 18, 2010
Millennium Initiates Phase II Trial for Diffuse Large B-Cell Lymphoma
Large, multi-center study to investigate VELCADE in genomically defined subtype of NHL.
Monday, October 26, 2009
CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer
CanBas and Takeda announce the advancement of CBP501 into Phase II clinical trials for the treatment of patients with non-small cell lung cancer.
Monday, July 13, 2009
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!